Pluri Inc.
PLURPluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How PLUR's past catalysts played out
No drugs found in this phase.
Frequently asked questions
When is Pluri Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Pluri Inc. (PLUR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PLUR biotech catalysts?→
Add PLUR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pluri Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.